<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614467</url>
  </required_header>
  <id_info>
    <org_study_id>CLBS16-P02</org_study_id>
    <nct_id>NCT04614467</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction</brief_title>
  <acronym>FREEDOM</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caladrius Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caladrius Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+&#xD;
      cells for the treatment of CMD in adults currently experiencing angina and with no&#xD;
      obstructive coronary artery disease. Eligible subjects will receive a single administration&#xD;
      of CLBS16 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in peak coronary flow reserve</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in angina frequency</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CCS angina class</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in total exercise time</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in health-related quality of life (HRQoL)</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Coronary Microvascular Dysfunction</condition>
  <condition>Coronary Microvascular Disease</condition>
  <condition>Microvascular Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>GCSF-mobilized autologous CD34+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLBS16</intervention_name>
    <description>GCSF-mobilized autologous CD34+ cells</description>
    <arm_group_label>GCSF-mobilized autologous CD34+ cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>isotonic solution (no CD34+ cells)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women age ≥18&#xD;
&#xD;
          -  History of and currently experiencing angina at least 3 times per week&#xD;
&#xD;
          -  Prior diagnosis of CMD based on coronary flow reserve (CFR) ≤ 2.5 or other measures&#xD;
&#xD;
          -  Peak CFR to intracoronary adenosine ≤ 2.5 at screening&#xD;
&#xD;
          -  Canadian Cardiovascular Society (CCS) class II, III or IV chronic refractory angina&#xD;
&#xD;
          -  No obstructive coronary artery disease&#xD;
&#xD;
          -  On stable medical therapy for at least 30 days prior to enrollment&#xD;
&#xD;
          -  Must agree to use a reliable and acceptable method of contraception for the duration&#xD;
             of participation&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction within 90 days&#xD;
&#xD;
          -  Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or&#xD;
             CABG)&#xD;
&#xD;
          -  Diagnosis of other specific cardiac disease&#xD;
&#xD;
          -  Must meet LVEF and GFR requirements&#xD;
&#xD;
          -  Current use of coumadin or DOACs&#xD;
&#xD;
          -  Hypersensitivity to GCSF, apheresis or study product components&#xD;
&#xD;
          -  Positive for HIV, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Active inflammatory or autoimmune disease, or chronic immunosuppressive state&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Malignant neoplasm within 5 years&#xD;
&#xD;
          -  History of Sickle Cell Disease&#xD;
&#xD;
          -  Participation in another clinical study within 90 days prior to informed consent or&#xD;
             concurrently with this study&#xD;
&#xD;
          -  Previous treatment with a CD34+ cell based therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Honigberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Caladrius Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Kotynski</last_name>
    <phone>9088420093</phone>
    <email>ckotynski@caladrius.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Sam</last_name>
      <phone>310-248-7651</phone>
      <email>Colleen.Sam@cshs.org</email>
    </contact>
    <investigator>
      <last_name>C. Noel Bairey Merz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Wei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida - College of Medicine/ div of Cardiovascular Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bostick</last_name>
      <phone>352-273-8938</phone>
      <email>Janette.Bostick@medicine.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah J Long, RN</last_name>
      <email>Sarah.Long@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>R. David Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Alaby, RN</last_name>
      <email>dalaby@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Ejaz</last_name>
      <email>Kiran.ejaz@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Arshed A Quyyumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute at Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Fox</last_name>
      <phone>612-863-6289</phone>
      <email>Jane.Fox@allina.com</email>
    </contact>
    <investigator>
      <last_name>Jay Traverse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Albers</last_name>
      <email>albers.diana2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Amir Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Rock, RN, MBA</last_name>
      <email>darlene.rock@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Timothy D. Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.freedom-trial.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angina</keyword>
  <keyword>CMD</keyword>
  <keyword>MVD</keyword>
  <keyword>non-obstructive coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Microvascular Angina</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

